Anti-tumour and anti-metastatic activity of 3-(P-Chlorophenyl)-2,3-Dihydro-3-Hydroxythiazolo (3,2-A)-Benzimidazole-2-acetic acid (WY-13,876).

Abstract

Extensive investigation of 3-(p-chlorophenyl)-2,3-dihydro-3-hydroxythiazolo(3,2-alpha)-benzimidazole-2-acetic acid (Wy-13,876) in BDF1 mice implanted with Lewis lung tumour has shown that it is an effective anti-tumour and anti-metastatic agent. In vitro examination using HEp-2 human epidermal tumour cells has indicated that Wy-13,876 is not cytotoxic. When mice implanted with Lewis lung tumour and treated with Wy-13,876 are also injected with anti-thymocyte serum, an increase in lung metastases is observed suggesting that thymocyte activity is involved in the drug's mechanism of action. An increase in peripheral T lymphocytes observed in rats 18 h after a single oral dose of Wy-13,876 further supports this possibility. When Wy-13,876 is given to tumour -bearing mice in combination with low, ineffective doses of 5-fluorouracil or cyclophosphamide, further reduction of primary tumour growth is observed.

• Authors: R L Fenichel, F J Gregory, H E Alburn
• Journal: British journal of cancer (Br J Cancer) Vol. 33 Issue 3 Pg. 329-35 (Mar 1976) ISSN: 0007-0920 [Print] England
• PMID: 1083737 (Publication Type: Journal Article)

Chemical References

• Anthelmintics
• Antilymphocyte Serum
• Antineoplastic Agents
• Benzimidazoles
• Thiazoles
• Levamisole
• Cyclophosphamide
• Fluorouracil

Topics

• Animals
• Anthelmintics (therapeutic use, toxicity)
• Antilymphocyte Serum
• Antineoplastic Agents (therapeutic use, toxicity)
• Benzimidazoles (therapeutic use, toxicity)
• Cyclophosphamide (therapeutic use)
• Fluorouracil (therapeutic use)
• Lethal Dose 50
• Levamisole (therapeutic use)
• Lung Neoplasms (drug therapy, immunology)
• Male
• Mice
• Neoplasm Metastasis (drug therapy)
• Neoplasm Transplantation
• Neoplasms, Experimental (drug therapy, immunology)
• T-Lymphocytes (immunology)
• Thiazoles (therapeutic use, toxicity)
• Transplantation, Isogeneic